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Abbreviations 
ALL  Acute lymphoblastic leukaemia 
BM Bone marrow 
CD Cluster of differentiation 
IQR Inter-quartile range 
LFS Leukaemia free survival 
MHC Major histocompatibility complex 
NK Natural killer 
OS Overall survival 
ROC Receiver operating characteristic 
WCC White cell count 
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Abstract  
Composition of tumour immune cell infiltrates correlate with response to treatment and overall 
survival (OS) in several cancer settings.  We retrospectively examined immune cells present in 
diagnostic bone marrow aspirate from paediatric patients with B-cell acute lymphoblastic 
leukaemia.  Our analysis identified a sub-group (~30% of patients) with >2.37% CD20 and 
>6.05% CD7 expression that had 100% OS, and a sub-group (~30% of patients) with ≤2.37% 
CD20 and ≤6.05% CD7 expression at increased risk of treatment failure (66.7% OS, p<0.05).  
Immune cell infiltrate at diagnosis may predict treatment response and could provide a means to 
enhance immediate treatment risk stratification.  
Introduction  1 
Conventional chemotherapeutic regimens cure a significant proportion of paediatric B cell acute 2 
lymphoblastic leukaemia (B-ALL) patients.  Improvements in survival rates observed over recent 3 
decades can be attributed to the introduction of efficient molecular testing for minimal residual 4 
disease during treatment, and new combinations of chemotherapeutics.  However, considerable 5 
adverse effect profiles are associated with regimens used to treat paediatric B-ALL.  Strategies to 6 
identify patients where lower dose treatment would be clinically effective or treatment 7 
intensification would enhance survival, represent attractive avenues to reduce long term 8 
cytotoxicity and/or enhance overall survival (OS).  9 
Recent advances in our understanding of tumour immunology suggest that an individual’s 10 
immune response, pre-therapy against their own tumour, significantly influences disease 11 
progression.[1]  Several parameters associated with the composition of immune infiltrate in solid 12 
tumours have been shown to correlate with prognosis, and in some instances, to predict patient 13 
survival more accurately than any other parameter.[2,3]  In B-ALL, two recent reports examining 14 
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the immunological composition of bone marrow (BM) at diagnosis demonstrate correlation 15 
between CD4+ T lymphocytes and favourable early response in paediatric patients[4] and CD8+ 16 
T lymphocytes and improved OS in adult patients.[5]  In this study, we examined the 17 
composition at diagnosis, of non-malignant lymphocytes in the BM of paediatric B-ALL 18 
patients.  We aimed to identify whether non-malignant lymphocytes routinely measured in BM 19 
aspirate by flow cytometry are associated with OS.  20 
Methods & Results 21 
We reviewed the medical records of 153 children diagnosed with ALL at Alder Hey Children’s 22 
Hospital, Liverpool between 2002 and 2009 in accordance with NHS Health Research Authority 23 
and Royal College of Pathologists’ guidelines.  All patients had been treated in accordance with 24 
UKALL 97/99 or UKALL 2003 trial protocol.  In 55 cases, flow cytometry data from clinical 25 
diagnostic BM aspirate could be recovered in List Mode data format and re-analysed to 26 
enumerate data related to the non-tumour cells present.  All 55 patients analysed were diagnosed 27 
with common ALL (de novo precursor B-ALL), patient characteristics are show in Table I.  28 
Patients with Philadelphia chromosome positive B-ALL, common ALL with aberrant CD20 29 
tumour expression or Down syndrome were excluded from this study.  There were 8 deaths and 30 
the remaining 47 patients were alive and well at the time of last follow up, although 4 had 31 
experienced relapse, but were treated successfully with salvage chemotherapy.   32 
We assessed the measured relative frequency values of CD markers in diagnostic BM aspirate 33 
between survivors and non-survivors.  Tumour lymphocytes (CD19+ CD10+) and non-malignant 34 
B-lymphocytes (CD19+ CD10-) were equivalent between study groups however, an increased 35 
relative frequency of the mature B lymphocyte marker, CD20, was observed in survivors 36 
(p=0.0295; Figure 1A).  T lineage cells (CD2+) were equivalent between study groups however, 37 
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an increased relative frequency of the mature T lymphocyte and NK cell marker, CD7, was 38 
observed in survivors (p=0.0447; Figure 1B).  Following associated Receiver Operating 39 
Characteristic (ROC) analysis, cut-offs of 2.37% CD20 expression (sensitivity 88%, specificity 40 
56%) and 6.05% CD7 expression (sensitivity 88%, specificity 53%) were selected to 41 
differentiate between patients with high and low expression.  Comparing patients with high 42 
CD20 expression (>2.37%; n=28) to those with lower expression (≤2.37%; n=27) we observed 43 
significantly increased OS of 96.4% compared to 74.1% (p=0.030; Figure 1C), and improved 44 
leukaemia free survival (LFS) of 92.9% compared to 66.7% (p=0.024; Figure 1D).  In a similar 45 
analysis of CD7, we observed increased OS of 96.0% in patients with high CD7 expression 46 
(>6.05%; n=25) compared to 76.7% in those with low expression (≤6.05%; n=30; p=0.041; 47 
Figure 1E) although no improvement in LFS was noted (Figure 1F).  Combining these factors, 48 
we observed patients with high CD20 expression and high CD7 expression (n=16), had 100% 49 
OS compared to 66.7% in patients with low expression of both markers (n=18; Figure 1G; 50 
p=0.013), and improved LFS of 87.5% compared to 61.1% (p=0.045; Figure 1H). 51 
Discussion 52 
Our retrospective analysis of CD marker expression in diagnostic BM aspirate identified a group 53 
of patients (16 out of 55), that could be characterised at diagnosis according to high CD20 and 54 
high CD7 expression, that experienced 100% OS.  Conversely, patients that could be 55 
characterised according to low CD20 and low CD7 expression (18 out of 55) experienced 56 
significantly reduced OS, 66.7%, suggesting that the BM immune infiltrate at diagnosis is 57 
indicative of, or can be correlated with, their response to treatment.  58 
An increasing body of literature exists linking immune system parameters at diagnosis with 59 
prognosis in cancer patients.[1]  Immune cell infiltrate may represent an ongoing but ineffective 60 
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antitumour immune response, or a collection of tumour promoting cells recruited into the tumour 61 
microenvironment.  This so called ‘tumour immune contexture’ may be relevant to 62 
understanding a patients’ response to treatment[6] and the induction of an antitumour immune 63 
response has the potential to enhance survival prospects.  Lymphocytes perform immune 64 
surveillance and may recognise malignant cells as immunogenic.[7]  CD20 is expressed on 65 
mature B cells with the exception of terminally differentiated plasmablasts or plasma cells.  66 
Resting B cells express surface Ig as a receptor,[8] antigen engagement of surface Ig can activate 67 
B cells, and leads to internalisation of antigen and presentation of peptides complexed with MHC 68 
class II at the cell surface for interaction with CD4+ T cells.[8,9]  Lymphocytes are also immune 69 
effector cells, and may mediate tumour cell death through granule exocytosis or death receptor 70 
signalling, cytotoxic T cells and NKs are key effectors in these mechanisms.  Interaction between 71 
B and T cells serves to augment adaptive immune responses through cross-priming of T cells, 72 
reciprocal enhancement of activation signalling in each cell type, and the production of 73 
immunostimulatory cytokines.[9,10]  Thus, the collaboration of different types of lymphocyte 74 
may confer the capacity to develop a robust adaptive immune response against autologous 75 
tumour cells.   76 
Our findings, combined with those reported by Lustfeld et al. (2014), provide the first 77 
information as to the relevance of the tumour immune contexture in paediatric ALL.  An 78 
increased frequency of mature immune cell components within the BM tumour 79 
microenvironment is strongly associated with both early treatment response[4] and successful 80 
chemotherapeutic treatment.  Further, elucidating the relationships between immune infiltrate 81 
components at diagnosis and treatment response may provide a means to enhance immediate 82 
treatment risk stratification.  Of the 8 children that died in this study, 3 had no clinical high risk 83 
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features and were treated according to Regimen A.  All 3 of these children had low CD20 84 
expression levels at diagnosis, and 2 of these 3 also had low CD7 expression levels.  Reliable 85 
identification of very good risk, and very high risk patients at diagnosis potentially offers the 86 
opportunity to reduce or intensify therapy from induction onward.  Our data clearly define two 87 
important patient sub-groups; firstly one for which the chemotherapeutic treatment regimen was 88 
100% successful, and secondly one where patients were at significantly increased risk of 89 
treatment failure.  Notwithstanding the limitations of this single centre retrospective study of 90 
small numbers, it seems relevant that the tumour immune contexture in paediatric ALL receive 91 
future attention.  Both to confirm our observations and to investigate mechanistically, the benefit 92 
to patients of mature immune cell BM infiltrate at treatment commencement.   93 
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Legends 130 
Figure 1.  CD20+ lymphocytes were increased in survivors compared to non-survivors (A), 131 
CD7+ lymphocytes were increased in survivors compared to non-survivors (B).  Enhanced OS 132 
(C) and LFS (D) was observed in paediatric B-ALL patients with >2.37% CD20+ lymphocytes.  133 
Enhanced OS (E) but not LFS (F) was observed in paediatric B-ALL patients with >6.05% 134 
CD7+ lymphocytes.  100% OS was observed in patients with >2.37% CD20+ and >6.05% CD7+ 135 
lymphocytes (G).  87.5% LFS was observed in patients with >2.37% CD20+ and >6.05% CD7+ 136 
lymphocytes compared to 61.1% LFS in patients with ≤2.37% CD20 and ≤6.05% CD7 137 
expression (H).  138 
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Table I.  Patient Characteristics 
 
Study cohort            
n=55 
Total patients 
n=153 
Median age in years, n (IQR) 5.0 (2.5 - 7.5) 4.0 (1.5 - 6.5) 
Male gender, n (%) 30 (54.5) 83 (54.2) 
Age groups:                                   
<10 years, n (%)                       
≥10 years, n (%) 
44 (80.0)                           
11 (20.0) 
125 (81.7)                  
28 (18.3) 
WCC at diagnosis:                   
<50 x 10
9
 L
-1
, n (%)                   
≥50 x 10
9
 L
-1
, n (%) 
46 (83.6)                      
9 (16.4) 
129 (84.3)                      
24 (15.7) 
Initial treatment protocol: 
Regimen A (low risk), n (%) 
Regimen B (high risk), n (%) 
36 (65.5)                    
19 (34.5) 
103 (67.3)                  
50 (32.7) 
  
IQR, inter-quartile range; WCC, white cell count.  
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Figure 1.  CD20+ lymphocytes were increased in survivors compared to non-survivors (A), CD7+ 
lymphocytes were increased in survivors compared to non-survivors (B).  Enhanced OS (C) and LFS (D) was 
observed in paediatric B-ALL patients with >2.37% CD20+ lymphocytes.  Enhanced OS (E) but not LFS (F) 
was observed in paediatric B-ALL patients with >6.05% CD7+ lymphocytes.  100% OS was observed in 
patients with >2.37% CD20+ and >6.05% CD7+ lymphocytes (G).  87.5% LFS was observed in patients 
with >2.37% CD20+ and >6.05% CD7+ lymphocytes compared to 61.1% LFS in patients with ≤2.37% 
CD20 and ≤6.05% CD7 expression (H).    
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